Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients

Figures & data

Table 1. Baseline characteristics of MM patients

Items	MM patients (N = 59)
Age (years)
Mean ± SD	54.5 ± 8.3
Median (IQR)	55.0 (48.0–61.0)
Male, No. (%)	35 (59.3)
Immunoglobulin subtype, No. (%)
Immunoglobulin G	30 (50.8)
Immunoglobulin A	12 (20.3)
Others	17 (28.8)
Bone lesion, No. (%)	44 (74.6)
Renal impairment, No. (%)	24 (40.7)
Hemoglobin (g/L)
Mean ± SD	97.4 ± 24.7
Median (IQR)	97.0 (83.0–113.0)
Calcium (mg/dL)
Mean ± SD	9.8 ± 2.1
Median (IQR)	9.7 (8.5–11.3)
Serum creatinine (mg/dL)
Mean ± SD	1.9 ± 0.9
Median (IQR)	1.8 (1.3–2.1)
Albumin (g/L)
Mean ± SD	32.5 ± 6.3
Median (IQR)	34.0 (28.0–37.0)
Beta-2-microglobulin (mg/L)
Mean ± SD	6.0 ± 3.9
Median (IQR)	5.4 (2.5–8.2)
Lactate dehydrogenase (U/L)
Mean ± SD	226.0 ± 103.0
Median (IQR)	204.8 (172.9–253.7)
Cytogenetics, No. (%)
t (4; 14)	7 (11.9)
t (14; 16)	3 (5.1)
Del (17p)	5 (8.5)
DS stage, No. (%)
I	0 (0.0)
II	6 (10.2)
III	53 (89.8)
ISS stage, No. (%)
I	6 (10.2)
II	24 (40.7)
III	29 (49.2)
R-ISS stage, No. (%)
I	3 (5.1)
II	29 (49.2)
III	27 (45.8)

MM, multiple myeloma; SD, standard deviation; IQR, interquartile range; DS, Durie-Salmon; ISS, International Staging System; R-ISS, revised International Staging System.

Figure 1. Lnc-ANGPTL1-3 and miR-30a expressions in MM patients and healthy donors. The comparison of lnc-ANGPTL1-3 expression (A) and miR-30a expression (B) between MM patients and healthy donors and the correlation between lnc-ANGPTL1-3 expression and miR-30a expression in MM patients (C) and health donors (D).

Figure 2. Associations of lnc-ANGPTL1-3 and miR-30a with cytogenetics in MM patients. The associations of lnc-ANGPTL1-3 expression (A) and miR-30a expression (B) with t (4; 14), t (14; 16), and Del (17p) in MM patients.

Figure 3. Associations of lnc-ANGPTL1-3 and miR-30a with disease stages in MM patients. The associations of lnc-ANGPTL1-3 expression (A) and miR-30a expression (B) with DS stage, ISS stage, and R-ISS stage in MM patients.

Figure 4. Associations of lnc-ANGPTL1-3 and miR-30a with treatment response in MM patients. The associations of lnc-ANGPTL1-3 expression (A) and miR-30a expression (B) with CR or ORR in MM patients.

Figure 5. Associations of lnc-ANGPTL1-3 and miR-30a with PFS and OS in MM patients. The association of lnc-ANGPTL1-3 expression with PFS (A) and OS (B) in MM patients and the association of miR-30a expression with PFS (C) and OS (D) in MM patients.

Figure 6. Associations of c-Maf and Beclin1 with lnc-ANGPTL1-3, miR-30a, PFS, and OS in MM patients. The association of c-Maf with lnc-ANGPTL1-3 (A), miR-30a (B), PFS (C), and OS (D); The association of Beclin1 with lnc-ANGPTL1-3 (E), miR-30a (F), PFS (G), and OS (H) in MM patients.